Press Releases

Year

May 10, 2021

Allakos Reports First Quarter 2021 Financial Results and Provides Business Update

REDWOOD CITY, Calif. , May 10, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter ended March 31, 2021

April 19, 2021

Allakos Appoints Baird Radford as Chief Financial Officer

REDWOOD CITY, Calif. , April 19, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that Baird Radford has been appointed Chief

March 30, 2021

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting

REDWOOD CITY, Calif. , March 30, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the acceptance of two oral and five poster

March 1, 2021

Allakos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

REDWOOD CITY, Calif. , March 01, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the fourth quarter and full year

Investors

Press Releases

(Common Stock)

Investor Toolkit